Arbutus Biopharma Corp
ABUS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001447028
No open-market purchases or sales by Arbutus Biopharma Corp insiders were filed in the last 90 days; 176 institutions reported holding it in 13F filings for Q2 2026, worth $674.9M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 11, 2026, 1:14 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $33.5M (237.9% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 23, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 5, 2023 | Jan 24, 2022 |
| Revenue | $14.1M | $6.17M | $18.1M | $39.0M | $11.0M |
| Operating expenses | $52.2M | $82.5M | $96.2M | $104.5M | $84.5M |
| Research and development | $25.2M | $54.0M | $73.7M | $84.4M | $65.5M |
| Selling, general and administrative | $15.9M | $22.1M | $22.5M | $17.8M | $17.1M |
| Operating income | -$38.2M | -$76.3M | -$78.1M | -$65.5M | -$73.5M |
| Interest expense | – | – | $459.0K | $1.73M | $2.86M |
| Income tax | $0 | $0 | $0 | $4.44M | $0 |
| Net income | -$33.5M | -$69.9M | -$72.8M | -$69.5M | -$76.2M |
| EPS, basic | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| EPS, diluted | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Weighted shares, basic | 191.6M | 185.6M | 166.0M | 150.9M | 106.2M |
| Weighted shares, diluted | 191.6M | 185.6M | 166.0M | 150.9M | 106.2M |
| Margins and growth | |||||
| Operating margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Net margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% |
| Revenue growth, year over year | +128.2% | −66.0% | −53.5% | +255.1% | +58.9% |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 23, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 5, 2023 | Jan 24, 2022 |
| Cash and equivalents | $18.0M | $36.3M | $26.3M | $30.8M | $109.3M |
| Short-term investments | $73.5M | $86.3M | $99.7M | $116.1M | $46.0M |
| Accounts receivable | $1.45M | $2.41M | $1.78M | $1.35M | $899.0K |
| Total current assets | $94.5M | $127.3M | $132.0M | $151.1M | $160.7M |
| Property, plant and equipment | $32.0K | $3.31M | $4.67M | $5.07M | $5.98M |
| Total assets | $94.6M | $131.7M | $144.4M | $195.4M | $204.5M |
| Total current liabilities | $6.01M | $15.6M | $22.5M | $32.9M | $11.2M |
| Long-term debt | $0 | $0 | $0 | $0 | $0 |
| Total liabilities | $18.0M | $34.3M | $38.4M | $58.6M | $35.0M |
| Shareholders' equity | $76.6M | $97.4M | $106.0M | $136.9M | $169.4M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Mar 23, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 5, 2023 | Jan 24, 2022 |
| Operating cash flow | -$39.6M | -$64.8M | -$85.9M | -$35.4M | -$67.5M |
| Capital expenditures | $0 | $182.0K | $1.01M | $512.0K | $809.0K |
| Free cash flow | -$39.6M | -$65.0M | -$86.9M | -$35.9M | -$68.3M |
| Stock-based compensation | $6.95M | $8.99M | $9.30M | $7.18M | $6.42M |
| Investing cash flow | $15.6M | $22.9M | $50.8M | -$74.9M | -$12.7M |
| Financing cash flow | $5.72M | $52.0M | $30.6M | $31.8M | $137.2M |
| Net change in cash | -$18.3M | $10.0M | -$4.49M | -$78.5M | $57.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 49.4% | 145.6% | 51.3% | 18.4% | 58.5% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 6, 2026 | 153.3M | −20.3% | SEC |
| Aug 10, 2026 | 197.8M | +3.2% | SEC |
| May 11, 2026 | 197.5M | +3.1% | SEC |
| Mar 18, 2026 | 195.5M | +2.1% | SEC |
| Nov 11, 2025 | 192.3M | +1.5% | SEC |
| Aug 4, 2025 | 191.7M | +1.5% | SEC |
| May 12, 2025 | 191.5M | +1.5% | SEC |
| Mar 25, 2025 | 191.5M | +6.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.